Biotech Innovator InstaMed Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform

Backed by successful double-blinded pharmacokinetic research data and nine pending patents, the biotechnology pioneer prepares for the August 3 launch of five next-generation oral dissolving peptide films.

InstaMed Pharmaceuticals, an advanced biotechnology organization renovating peptide delivery via its patented InstaRelease oral dissolving strip platform, announced the appointment of Tracy Gibbs, PhD, as Chief Executive Officer. The leadership transition marks a significant milestone for the 14-month-old organization as it accelerates the global expansion of its needle-free peptide delivery solutions.

Gibbs, PhD, is a nationally recognized formulator with decades of experience in nutrient absorption science, botanical biochemistry, and well-delivery services. Under his leadership, InstaMed is developing a proprietary platform designed to provide a clinical-grade, non-invasive substitute to traditional injectable peptide therapies.

Gibbs, PhD, is a nationally recognized formulator with decades of experience in nutrient absorption science, botanical biochemistry, and well-developed delivery technologies. Under his leadership, InstaMed is advancing a proprietary platform intended to offer a clinical-grade, non-invasive substitute to traditional injectable peptide solutions.

The platform was recently validated via double-blinded pharmacokinetic (PK) research demonstrating faster absorption and more consistent circulating peptide levels with oral dissolvable strip delivery as compared to traditional administration processes.

"The peptide industry is evolving rapidly, and expanding patient access depends on delivery technologies that are both effective and convenient," said Tracy Gibbs, PhD, Chief Executive Officer of InstaMed Pharmaceuticals. "Our clinical data demonstrates that patients no longer have to choose between therapeutic performance and a non-invasive delivery method. By combining rigorous science with a shelf-stable, travel-friendly platform, we're helping make advanced peptide solutions more accessible to both healthcare providers and consumers worldwide."

According to Towards Healthcare, the U.S. compounding pharmacy market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 7.42 billion in 2026 to approximately USD 12.79 billion by 2035. CAGR of 6.24% between 2026 and 2035. Compounding pharmacies can also help bridge the gap during medication shortages or discontinuations. By creating equivalent formulations, they ensure patients continue receiving the therapies they need without interruption. This capability is particularly beneficial for rare or niche medications that may no longer be commercially available. Compounding increase medicine adherence by providing adapted dosages and formulations. Once a drug is easy to use, free of irritants, and customized to the consumer's preferences, the patient is more possible to take it. Better management outcomes and an improved quality of life result from this approach. Compounding pharmacies are significant to contemporary medical care as they provide customized services that cater to each patient's specific demands. When it comes to pediatric care, allergies, or medicine shortages, compounding provides a versatile and effective substitute for mass-produced medicines.

About InstaMed

InstaMed powers a better healthcare payments experience on one platform that connects consumers, providers and payers for every healthcare payment transaction. InstaMed’s patented, private cloud-based technology securely transforms healthcare payments by driving electronic transactions, moving money and healthcare data seamlessly, and improving consumer satisfaction. Everybody benefits from InstaMed’s exclusive focus on medical care, incorporating in the any healthcare IT system advance analytics and proven scale. InstaMed powers an advanced medical care payments experience on one platform that connects consumers, providers, and payers for each healthcare payment transaction.

A recent report by Towards Healthcare highlights that the U.S. compounding pharmacy market is growing as compounding pharmacies offer tailored strategies to healthcare, providing customized medications intended to meet the particular needs of every patient. Unlike mass-produced biopharmaceuticals, compounded medications are created by licensed pharmacists who adjust ingredients, dosages, and formulations to suit separate requirements. Compounding is its capability to offer targeted treatments. For patients with allergies or sensitivities to some ingredients, compounding enables pharmacists to remove dyes, preservatives, or other irritants from therapeutics. Compounding is its capability to offer targeted treatments. Compounding can increase medication adherence by providing modified dosages and formulations. When a drug is easy to use, free of irritants, and customized to the patient's preferences, the patient is more likely to take it. Advanced treatment outcomes and an improved quality of life result from this approach.